BMT CTN Protocol 0502

A Phase II Study of Allogeneic Transplant for Older Patients with AML in First Morphologic Complete Remission using a Non-myeloblative Preparative Regimen

Below are protocol-related doucments, which may be periodically updated.

            CALGB Protocol Chair: Steven Devine, MD (614-293-9868)

            BMT CTN Protocol Chair: Sergio Giralt, MD (212-639-3859)

            Alliance Regulatory Group:


This trial is a collaboration between Cancer and Leukemia Group B (CALGB) and BMT CTN. Patient accrual on CALGB 100103/BMT CTN 0502 closed on December 29, 2011.